1-(4-(4-(6-fluoro-1H-indol-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)ethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(4-(4-(6-fluoro-1H-indol-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)ethanone
• 英文别名: 1-[4-[4-(6-fluoro-1H-indol-3-yl)pyrazol-1-yl]piperidin-1-yl]ethanone
• 化学式: C₁₈H₁₉FN₄O
• 分子量: 326.373
• InChiKey: BCPHTDUFOQTXAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  53.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
  申请人：ITEOS THERAPEUTICS

  公开号：US20150133422A1

  公开（公告）日：2015-05-14

  The present invention embodiments relate to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates in certain embodiments to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates in certain embodiments to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates in certain embodiments to a process for manufacturing compounds of Formula I.

  本发明实施例涉及化合物I的化合物或其药用可接受的对映体、盐或溶剂合物。在某些实施例中，本发明还涉及将化合物I用作TDO2抑制剂。在某些实施例中，本发明还涉及将化合物I用于治疗和/或预防癌症、帕金森病、阿尔茨海默病和亨廷顿病等神经退行性疾病、慢性病毒感染如丙型肝炎病毒和人类免疫缺陷病毒感染、抑郁症和肥胖症。在某些实施例中，本发明还涉及制造化合物I的方法。
• 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
  申请人：iTeos Therapeutics

  公开号：EP3066090A1

  公开（公告）日：2016-09-14
• US9126984B2
  申请人：——

  公开号：US9126984B2

  公开（公告）日：2015-09-08
• [EN] 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE<br/>[FR] DÉRIVÉS DE 4-(INDOL-3-YL)PYRAZOLE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION
  申请人：ITEOS THERAPEUTICS

  公开号：WO2015067782A1

  公开（公告）日：2015-05-14

  The present invention relates to compound of Formula (I) or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as tryptophan 2,3-dioxygenase (TDO2) inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula (I).